Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Compass Therapeutics ( (CMPX) ) is now available.
On August 12, 2025, Compass Therapeutics announced an underwritten public offering of its common stock and pre-funded warrants, expected to close around August 14, 2025. The company aims to raise approximately $112.5 million from the offering to fund commercial readiness, research, and clinical development, with cash reserves projected to support operations into 2028.
The most recent analyst rating on (CMPX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Compass Therapeutics stock, see the CMPX Stock Forecast page.
Spark’s Take on CMPX Stock
According to Spark, TipRanks’ AI Analyst, CMPX is a Neutral.
Compass Therapeutics’ stock is moderately attractive, driven by strong market momentum and strategic leadership changes. However, significant operational losses, negative cash flows, and lack of current profitability weigh down the financial performance score. While technical indicators are positive, valuation remains a concern due to the negative P/E ratio.
To see Spark’s full report on CMPX stock, click here.
More about Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company based in Boston, Massachusetts. It develops proprietary antibody-based therapeutics aimed at treating multiple human diseases, with a focus on the relationship between angiogenesis, the immune system, and tumor growth.
Average Trading Volume: 838,822
Technical Sentiment Signal: Strong Buy
Current Market Cap: $438.4M
For detailed information about CMPX stock, go to TipRanks’ Stock Analysis page.